

Pneumoconiosis Market Analysis 2025 – Insights For Long-Term Investment & Planning

*The Business Research Company's
Pneumoconiosis Global Market Report
2025 – Market Size, Trends, And Global
Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, July 24, 2025

/EINPresswire.com/ -- How Has The
Pneumoconiosis Market Grown And
What Are Its Future Projections?

The [pneumoconiosis market size](#) has grown steadily in recent years. It will grow from \$1.43 billion in 2024 to \$1.49 billion in 2025 at a compound annual growth rate CAGR of 4.7%. The growth in the historic period can be attributed to the increasing prevalence of occupational lung diseases, rising industrialization in emerging economies, growing awareness about workplace safety, increasing government regulations on industrial dust exposure, and the rising number of coal and silica mining operations.

“

The Business Research
Company's Latest Report
Explores Market Driver,
Trends, Regional Insights -
Market Sizing & Forecasts
Through 2034”

*The Business Research
Company*

What Is Its Annual Growth Rate?

The pneumoconiosis market size is expected to see steady growth in the next few years. It will grow to \$1.77 billion in 2029 at a compound annual growth rate CAGR of 4.4%. The growth in the forecast period can be attributed to the growing geriatric population, increasing adoption of

advanced imaging and diagnostic technologies, rising healthcare expenditure, growing investments in respiratory disease research, and increasing litigation and compensation claims. Major trends in the forecast period include advancements in diagnostic imaging, integration of artificial intelligence AI in radiology, technology-enabled remote monitoring, developments in wearable respiratory monitoring devices, and advancements in pulmonary drug delivery systems.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24661&type=smp>

The Business
Research Company

Pneumoconiosis Global Market Report 2025



What Is The Key Growth Driver Of The Pneumoconiosis Market?

The rising exposure to asbestos is expected to propel the growth of the pneumoconiosis market going forward. Asbestos exposure occurs when a person inhales or comes into contact with asbestos fibers, potentially causing severe health conditions like asbestosis, mesothelioma, and lung cancer. Asbestos exposure is increasing as renovations and demolitions of old buildings release harmful fibers into the air, raising inhalation risks. Inhalation of asbestos fibers can lead to pneumoconiosis, as the fibers become lodged in the lungs and cause persistent inflammation. This ongoing irritation results in lung scarring fibrosis, which gradually impairs breathing and overall lung function. For instance, in July 2024, according to the report published by the UK Asbestos Training Association UKATA, a UK-based training and awareness organization, over 5,000 asbestos-related disease deaths occur annually in the UK, with 493 asbestosis-related deaths in 2022, while over 70% of these deaths are in individuals aged over 75. Therefore, the increasing exposure to asbestos is driving the growth of the pneumoconiosis market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/pneumoconiosis-global-market-report>

Who Are The Key Industry Players In The Pneumoconiosis Market?

Major companies operating in the pneumoconiosis market are AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk, Koninklijke Philips NV, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals Inc., Inogen, GNI Group Ltd., and DRIVE MEDICAL GMBH & CO. KG.

What Are The Emerging Trends In The Industry?

Major companies operating in the pneumoconiosis market are focused on developing advanced solutions, such as clinical trials for pneumoconiosis medication to improve treatment efficacy, slow disease progression, and enhance patient outcomes. For instance, in June 2022, Beijing Continent Pharmaceutical Co. Ltd., a pharmaceutical company based in China, enrolled the first subject in a Phase III clinical trial for Pirfenidone Capsules F647, aimed at treating pneumoconiosis, a serious occupational lung diseases caused by inhalation of dust leading to fibrosis.

How Is The [Pneumoconiosis Market Segmented](#)?

The pneumoconiosis market is segmented by type of pneumoconiosis, diagnosis, treatment, distribution channel, and end-user. It also covers several sub-segments including various forms of asbestosis, silicosis, coal workers' pneumoconiosis, and berylliosis.

Which Regions Experienced The Most Market Growth?

North America was the largest region in the pneumoconiosis market in 2024. However, Asia-Pacific is projected to be the fastest-growing region in the forecast period. The regions covered in this report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America,

the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Apheresis Consumables And Equipment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/apheresis-consumables-and-equipment-global-market-report>

Psoriasis Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report>

Hemostasis Analyzers Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/hemostasis-analyzers-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/829002987>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.